Tripartite motif-containing protein 5a (TRIM5a) functions as a cellular antiviral restriction 34 factor with exquisite specificity towards the capsid lattices of retroviruses. The relative avidity 35 of TRIM5a binding to retrovirus capsids directly impacts primate species susceptibility to 36 infection, but the antiviral role of TRIM5a is thought limited to retroviruses. In contrast to this 37 current understanding, here we show that both human and rhesus TRIM5a possess potent 38 antiviral function against specific flaviviruses through interaction with the viral protease 39 with exquisite specificity, thought to restrict only retroviruses through complex interactions 84 with the capsid lattice structure that accelerates uncoating of the viral nucleic acid and also 85 blocks reverse transcription [9][10][11] . The significant influence of TRIM5a is exemplified by the 86 observations that its antiviral activity drives lentivirus evolution 9 and limits cross-primate 87 species transmission 12 . Importantly, the relative ability of TRIM5a to bind retrovirus capsid 88 lattices directly impacts primate species susceptibility to infection. For example, TRIM5a from 89 4
as the viral protease, whereas NS5 possesses both methyltransferase (MTase) and RNA-61 dependent RNA polymerase (RdRP) activities. 62
63
The repeated emergence of flaviviruses as human pathogens is in part due to the fact that they 64 are arthropod-borne, transmitted by mosquitoes and ticks. In addition, the zoonotic reservoir 65 species' supporting virus replication in nature are highly diverse. For example, small mammals, 66 particularly rodents, are thought critical for maintenance of transmission cycles of TBEV and 67 related viruses. In contrast, WNV utilizes birds, whereas DENV, ZIKV and YFV evolved in non-68 human primates before at least DENV and ZIKV established urban transmission cycles 69 maintained exclusively through human infections 4 . The ability of a virus to avoid or evade host 70 antiviral responses is essential to establish replication and transmission 5 . However, it is not 71 fully understood how evolution in different reservoir hosts to avoid innate immunity has 72 shaped replication and pathogenesis of different flaviviruses following infection of humans. 73
Host-specific interactions with the interferon (IFN) response have been demonstrated for DENV 74
and ZIKV that can only antagonize IFN-dependent signaling in the context of primate hosts 6 . 75
However, the IFN-stimulated genes (IGSs) that might also contribute to host-specific restriction 76 of flaviviruses are not well characterized. TRIMs exist in the human genome 7 , many of which are ISGs with functions as direct antiviral 81 restriction factors or as modulators of the cellular response to infection 8 . The most 82 characterized primate TRIM is TRIM5a, which functions as a cellular antiviral restriction factor 83 with exquisite specificity, thought to restrict only retroviruses through complex interactions 84 with the capsid lattice structure that accelerates uncoating of the viral nucleic acid and also 85 blocks reverse transcription [9] [10] [11] . The significant influence of TRIM5a is exemplified by the 86 observations that its antiviral activity drives lentivirus evolution 9 and limits cross-primate 87 species transmission 12 . Importantly, the relative ability of TRIM5a to bind retrovirus capsid 88 lattices directly impacts primate species susceptibility to infection. For example, TRIM5a from 89 G) pseudotyped HIV-1 in 293 cells, demonstrating that these cells are appropriate to observe 119 TRIM5-mediated restriction ( Supplementary Fig. 1b ). Compared to empty vector control cells, 120 expression of either human (h) TRIM5a or rhTRIM5a restricted replication of related viruses in 121 the TBEV serogroup, including TBEV (strain Sofjin), Kyasanur Forest disease virus (KFDV) and 122
Langat virus (LGTV; an attenuated member of the TBEV serocomplex), but not WNV (strain NY99), 123 DENV (strain NGC, serotype 2), ZIKV (strain 2013 French Polynesia) or YFV (strain 17D) (Fig. 1a) . 124
TRIM5a did not affect replication of Powassan virus (POWV; strain LB) despite this virus also 125 belonging to the TBEV serogroup. The impact of hTRIM5a or rhTRIM5a on replication of sensitive 126 flaviviruses was significant, reducing production of infectious virus by up to 1000-fold during the 127 exponential phase of virus growth. hTRIM5a was functional but less efficient, imposing a 90% 128 reduction but this may be attributable to the lower expression of hTRIM5a compared to 129 rhTRIM5a ( Supplementary Fig. 1a ). Therefore, we also used CrFK cells stably expressing 130 hTRIM5a-HA as a cell model historically used to examine retrovirus restriction as they lack 131 intrinsic TRIM5a expression 17 . Expression of hTRIM5a suppressed replication of both TBEV 132 ( Supplementary Fig. 1c ) and LGTV (data not shown), but not WNV ( Supplementary Fig. 1d ). In 133 HEK293 cells that support more optimal flavivirus growth, restriction was observable up to a 134 starting multiplicity of infection (MOI) of 10 ( Supplementary Fig. 1e ), but replication of TRIM5a-135 sensitive viruses eventually overcame restriction which is consistent with viral saturation of 136 antiviral restriction factors 18 (Fig. 1a) . A related human TRIM with anti-retrovirus function, 137
TRIM22
1919191919 , did not impact replication of TBEV, KFDV or LGTV, demonstrating a specific role 138 for TRIM5a in flavivirus restriction (Fig. 1a) . Suppressed replication of KFDV was also observed at 139 the level of protein expression, with reduced accumulation of NS3 in cells expressing hTRIM5a-140 HA or rhTRIM5a-HA compared to the empty vector controls (Fig. 1b) . Expression of the envelope 141
protein (E) of sensitive viruses was also reduced when examined by flow cytometry (Fig. 1d) . 142
However, no reduction in either NS3 by Western blot or E expression by flow cytometry was 143 observed following POWV infection, supporting flavivirus species-specific restriction by TRIM5a 144 (Fig. 1c, d) . 145
146
To determine if human TRIM5a is a functional restriction factor, TRIM5 mRNA was depleted by 147 RNA interference (RNAi) in A549 cells using lentivirus-delivered short hairpin RNA (shRNA), or 148 TRIM5 was knocked out using CRISPR/Cas9 in Hap1 cells. Cells were left untreated, or treated 149 with IFNb for 6 h prior to infection to upregulate TRIM5 expression and induce an antiviral state. 150
Reduced TRIM5 expression did not affect the responsiveness of cells to IFNb as measured by 151 upregulation of canonical IFN-stimulated genes (ISGs), RSAD2 (viperin) and CXCL10 (Fig. 2a) . 152
However, depletion of TRIM5 partially relieved the antiviral effect of IFNb on LGTV (Fig. 2a) . 153
Transfection of A549 cells with an independent siRNA sequence targeted towards hTRIM5a also 154 increased replication of LGTV but not YFV (Fig. 2b) . Furthermore, deletion of TRIM5 using 155 CRISPR/Cas9 in Hap1 cells ( Supplementary Fig. 1f,g ) rescued ~2 log10 LGTV replication in the 156 presence of IFNb (Fig. 2c) . Virus replication was also increased for TBEV, but not POWV, WNV, 157 ZIKV, DENV or YFV (Fig. 2c) . Together, these results identify TRIM5a as a restriction factor for 158 specific species of flaviviruses, and demonstrate that TRIM5a is an effector of the human type I 159 IFN response to these viruses. 160
161
TRIM5a expression restricts viral RNA replication.
162
To determine which step in the flavivirus life cycle was restricted by TRIM5a, LGTV replication 163 was examined in rhTRIM5a-HA HEK293 cells. At 48 hours post infection (hpi) supernatants and 164 cell lysates were subjected to three cycles of freeze-thaw lysis to compare levels of intra-and 165 extra-cellular virus. In the presence of rhTRIM5a, no change in the ratio (~1:10) of 166 intracellular:extracellular infectious virus was observed (Fig. 3a) although intracellular 167 accumulation of positive-sense (genomic) viral RNA was reduced by approximately 50-fold (Fig.  168   3b ). Viral entry was not affected as differences in positive-sense RNA were not apparent after 169 virus entry until at least 8-12 hpi when flavivirus RNA replication is initiated 3,20 (Fig. 3c) . Thus, 170
TRIM5a imposes a block in virus replication at or preceding RNA replication without affecting 171 virus entry or release. In flavivirus-infected cells, cellular localization of dsRNA is an obligate 172 marker of sites of replication, and most perinuclear foci containing NS3 (the viral protease and 173 RNA helicase) also colocalize with dsRNA, suggesting these perinuclear foci are sites of active 174 replication 21 ( Supplementary Fig. 2a) . In infected cells, small aggregates of rhTRIM5a often 175 termed cytoplasmic bodies 22 colocalized with NS3 and dsRNA suggesting that TRIM5a is 176 recruited to replication complexes (Fig. 3d) . RhTRIM5a aggregates also colocalized with NS5 (the 177 viral RdRP) but only at perinuclear sites likely together with NS3 at the ER (Fig. 3e) . Recruitment 178 of human TRIM5a to sites of NS3 expression was also observed in LGTV-infected cells 179
( Supplementary Fig. 2b ). Areas of colocalization were observable between TRIM5a and dsRNA in 180 the context of DENV or ZIKV, but unlike LGTV, infection did not induce strong aggregation of 181 TRIM5a ( Supplementary Fig. 3a,b) . Next, we validated the association of either hTRIM5a or 182 rhTRIM5a with NS3 by immunoprecipitation (IP) in LGTV-infected cells (Fig. 3f) . Despite low levels 183 of viral protein associated with restriction, IP of NS3 from infected cells resulted in co-184 precipitation with either hTRIM5a or rhTRIM5a (Fig. 3f) . As expected, NS5 also co-precipitated 185 with NS3 in infected cells which supports the IFA data and suggests that TRIM5a interactions 186 with NS3 occur at sites of virus replication where NS3 and NS5 interact. Consistent with lack of 187 TRIM5a aggregation at sites of dsRNA staining ( Supplementary Fig. 2c, d ), IP of NS3 from WNV-188 infected cells did not result in co-precipitation of rhTRIM5a ( Supplementary Fig. 2e ). to ER membranes, with NS2B/3 being an important antiviral drug target 23 .
LGTV NS5 showed 197 some co-localization with rhTRIM5a ( Fig. 4a) and caused low levels of TRIM5a aggregation (Fig.  198 4b) but did not co-precipitate ( Supplementary Fig. 4a ). However, LGTV NS2B/3 expression caused 199 rhTRIM5a to aggregate into discrete cytoplasmic bodies (Fig. 4a,b and Supplementary Fig. 4b ) 200 and co-localize reminiscent of that observed following virus infection, and LGTV NS2B/3 strongly 201 associated with rhTRIM5a by co-precipitation (Fig. 4g ). In addition, expression levels of NS2B/3 202 were reduced in cells expressing rhTRIM5a compared to the control cell line, whereas NS5 levels 203
were not strongly affected (Fig. 4c) . To further explore this observation, a constant level of LGTV 204 NS2B/3 was expressed with increasing amounts of either rhTRIM5a or hTRIM5a by transfection 205 of expression plasmids. In either case, expression of both unprocessed NS2B/3 and NS3 206 generated through autonomous cleavage was reduced in a dose-dependent fashion (Fig. 4d,e) , 207 although this effect was quickly saturated. Again, expression of LGTV NS5 was not affected by 208 rhTRIM5a expression (Fig. 4f) . 209
210
In the context of HIV-1, TRIM5a utilizes the proteasome (MG132 sensitive) for capsid disruption 211 but not for restriction 24 , and may also use lysosomes following autophagy (BafA1-sensitive) to 212 degrade the capsid 25, 26 . Treatment of NS2B/3-expressing cells with BafA1 to inhibit lysosomal 213 degradation increased expression of NS2B/3 when expressed alone but did not rescue the 214 relative loss of NS2B/3 in the presence of rhTRIM5 (Fig. 4h,i) . This was despite the BafA1-sensitive 215 rescue of p62/SQSTM1 which is a reported co-factor to TRIM5-mediated retrovirus restriction 27 216 ( Fig. 4h) . Selective autophagy of the HIV-1 capsid by TRIM5a is also mediated by Beclin, ATG5, 217 p62, GABARAP and LC3
26 , but siRNA-mediated knockdown of these genes did not significantly 218 relieve LGTV restriction ( Supplementary Fig. 5a,b,c) . Finally, the C-type lectin langerin, but not 219 DC-SIGN, was previously shown to be sufficient for autophagic degradation of HIV-1 capsid by 220 hTRIM5a 25 . However, while DC-SIGN augmented LGTV replication as expected in its role as a 221 flavivirus attachment factor 28 , langerin expression had no effect and did not further increase the 222 restriction of LGTV in TRIM5a expressing cells ( Supplementary Fig. 5d ), strongly suggesting that 223 selective autophagy following virus entry or establishment of viral replication complexes is not 224 the main mechanism of restriction. In contrast, treatment with epoxomicin ( Fig. 4h,i) recovered 225 the majority of NS3 in the presence of rhTRIM5a implicating proteasomal degradation of NS2B/3. 226
This was supported by reciprocal IP of NS2B/3 ectopically co-expressed with rhTRIM5 in the 227 presence of epoxomicin demonstrating a) increased interactions between TRIM5a and both the 228 uncleaved NS2B/3 precursor and the mature, autocleaved NS3 protein, and b) increased 229 ubiquitination of NS2B/3 co-precipitating with TRIM5a ( Fig. 4g ). TRIM5a did not appear to affect 230 protease activity as autocleavage to produce NS3 measured by the ratio of NS2B/3:NS3 did not 231 change in the presence of TRIM5a ( Supplementary Fig. 5e ). Furthermore, overexpression of 232 K48R-HA ubiquitin (Ub) that cannot make K48-linked Ub chains, but not K63R-HA Ub, rescued 233 expression of both NS2B/3 and rhTRIM5a ( Fig. 4j) , further suggesting that NS2B/3 degradation 234 involves K48-linked ubiquitination which generally involves the proteasome. 235
236
To determine the domain of NS2B/3 recognized by TRIM5a, degradation assays were performed 237 on various truncated NS2B/3 constructs (Fig. 4k). LGTV NS3 expressed without NS2B 238 ( Supplementary Fig. 5f ) or the NS3 helicase domain alone ( Supplementary Fig. 5g ) was not 239 sufficient for TRIM5a-mediated degradation. A construct containing the entire NS2B protein 240 fused to the NS3 protease domain (NS2B-NS3pro) was also not degraded suggesting that NS2B 241 alone is not sufficient as a target ( Supplementary Fig. 5h ). However, expression of NS3pro 242 containing the 40 amino acids of NS2B required for NS3 protease activity in frame with a flexible 243 glycine linker, the NS3 protease domain and the linker sequence between the NS3 protease and 244 helicase domains, enabled degradation (Fig. 4l) . Thus, the target for TRIM5a degradation 245 requires NS2B in addition to NS3 sequences (NS3pro). Recognition of NS2B/3 is therefore likely 246 dependent on protease conformation, but is independent of protease activity as the S138A active 247 site mutant of NS2B/3 was also degraded ( Supplementary Fig. 5i ). The specificity of TRIM proteins is mainly determined by their C-terminal B30.2/SPRY domain that 255 is responsible for binding to specific substrates including retroviral capsids 15 . The C15/18A RING 256 mutant of rhTRIM5a did not degrade NS2B/3 (Fig. 5a ) and instead stabilized it consistent with 257 retention of binding (Fig. 5b) . Restriction of infectious virus production was also dependent on 258 rhTRIM5a RING function, particularly at early times post infection (Fig. 5d ). Compared to co-259 expression of LGTV NS2B/3 with WT-rhTRIM5a-HA, the C15/18A RING mutant retained strong 260 colocalization by IFA, but lost the ability to form discrete cytoplasmic bodies ( The role of human TRIM5a in suppression of HIV-1 has been controversial, in part because early 281 studies suggested no restriction of laboratory strains of HIV-1. However, recent studies suggest 282 that cytotoxic T lymphocyte (CTL)-selected HIV-1 isolates from so-called 'elite controllers' are 283 susceptible to restriction by human TRIM5a 38 , and genetic studies suggest that human 284 polymorphisms in TRIM5 impact disease progression 13 . To further examine whether TRIM5a in 285 human cells restricts flavivirus replication, we first immunoprecipitated LGTV NS2B/3 following 286 ectopic expression in unmodified HEK293 cells which revealed an interaction with endogenous 287 TRIM5a (Fig. 6a) . Treatment of these cells with epoxomicin increased the levels of co-288 precipitating TRIM5 and NS2B/3 as well as the presence of endogenous K48-linked Ub smears in 289 the complex (Fig. 6b) , whereas depletion of TRIM5a by CRISPR/Cas9-mediated gene editing both 290 increased levels of NS3 and decreased endogenous K48-linked Ub smears in the precipitates (Fig.  291 6c) . Endogenous interactions between NS3 and TRIM5a were also confirmed in the HAP1 cells 292 knocked out for TRIM5a by CRISPR/Cas9 and infected with LGTV (Fig. 6d) . Finally, infection of 293 primary human monocyte derived dendritic cells (DCs) resulted in upregulation of TRIM5 294 expression (Fig. 6e) . Silencing of TRIM5 expression in human DCs by lentivirus-delivered shRNA 295 expression 39 increased release of infectious KFDV by approximately 170 fold at 48 hpi compared 296 to cells expressing shRNA specific for luciferase as a control (Fig. 6f,g ). No effect of TRIM5a 297 silencing was observed following infection with ZIKV (Fig. 6h) . Together, these data demonstrate 298 that human TRIM5a is a bona fide restriction factor for specific flaviviruses that functions through 299 interactions with the viral replication complex and proteasomal degradation of NS3. ultracentrifuged over a cushion consisting of 25% sucrose in TNE buffer (10 mM Tris-HCl, pH 410 7.5, 1 mM EDTA, 100 mM NaCl, pH 7.4) at 28,000 rpm in a SW-28 Rotor (Beckman). Lentivirus 411 pellets were resuspended in PBS, aliquoted, and stored at -80°C prior to use. shRNA-luc and 412
shRNA-TRIM5 lentivirus titers were normalized by serial dilution on HEK293 cells followed by 413 puromycin selection. 414
415

Knockdown of TRIM5 in Human monocyte-derived dendritic cells (hMDDC) cultures 416
Human monocyte cultures 46 were seeded in 48-well plates and transduced with a combination 417 of vpx-vlp and shControl or shTRIM5 lentivirus for three hours followed by addition of IL-4 and 418 GM-CSF-conditioned RPMI media. rhesus TRIM5delB30.2 constructs were generated using pLPCX templates and primers that 439 amplify aa 1-276 from human TRIM5 or 1-278 from rhesus TRIM5. All above PCR reactions were 440 carried out using PCR Supermix High Fidelity (Thermo Fisher; 10790020) with an annealing 441 temperature of 58°C. Constructs were TA-cloned into the gateway entry plasmid pCR8 442 (Invitrogen; K2500-20). An LR Clonase II reaction (Invitrogen; 11791-100) was used to move 443 these constructs into a Gateway-converted pLPCX retroviral packaging vector (Clontech; 444 631511). The RING C15/18A mutant of TRIM5 was generated using PfuTurbo DNA polymerase 445 (Stratagene; 600250) with an annealing temperature of 55°C. Parental pLPCX plasmids were 446 used as a template along with primers containing the mutations of interest. Constructs 447 expressing LGTV and WNVNY99 NS2B/3 and NS5 were generated as previously described 44 . 448 Igepal, and 0.5% Na-deoxycholate) with protease inhibitor cocktail (Roche). For IPs of over-490 expressed proteins, 2 wells of a 6 well dish at 1x10 6 cells/well were used per reaction; for IPs of 491 virus-infected stable TRIM5 HEK293 cells, a 10cm dish of 7x10 6 cells/dish was used per reaction; 492 for detection of endogenous TRIM5, HEK293 or HAP1 cells were grown to confluency in 3-4 493 T150 tissue culture flasks. Samples were subjected to centrifugation for 10 min at maximum 494 speed to remove cellular debris. Protein G-conjugated agarose beads (Roche) or PrecipHen for 495 chicken antibodies (Aves Labs) were used to clear cell lysates at 4°C for 3 h. Samples were 496 centrifuged to remove beads, and 2 μg of antibody analogous to the protein of interest was 497 added to each lysate for 1 h with rotation at 4°C. 50 µl protein G-agarose or PrecipHen beads 498 and were incubated with rotation at 4°C overnight. Lysates were subjected to centrifugation, 499 and beads were washed three times with RIPA buffer prior to elution by incubation at 95°C in 500 1× sample buffer (62.5 mM TRIS [pH 6.8], 10% glycerol, 15 mM EDTA, 4% 2-ME, 2% SDS, and 501 bromophenol blue). For western blot analysis HEK293 cell lines were grown to confluency in a 502
12-well or 6-well dish, collected using a cell scraper, and lysed in RIPA buffer containing 503 complete protease inhibitor (Roche, #11836170001). After quantification of protein 504 concentration using a Bradford assay, 30 µg of whole cell extract was resolved using a 10% 505 polyacrylamide gel and transferred to a nitrocellulose membrane. Ubiquitination assays were 506 supernatants by plaque assay. All data are from three independent experiments performed in 689 triplicate (mean ± s.d., *P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001, n.s. not significant). 690
Grey dotted line indicates limit of detection. LGTV titers in A549 cells that were left untreated or pre-treated with IFNb for 6 h and infected 701 at MOI-0.001. Supernatants were collected at the indicated times and titrated by plaque assay. 702
All data are from three independent experiments performed in triplicate (mean ± s.d., *P < 703 0.05, **P < 0.01 by Mann-Whitney; ns, not significant). 
